Aurelium BioPharma

Aurelium BioPharma is dedicated to the discovery and validation of cancer biomarkers. It provides a series of biomarkers for the development of diagnostic tests for breast cancer, ovarian cancer, lung cancer, colon cancer, and prostate cancer, as well as for predicting the initial response to first-line chemotherapy in ovarian cancer. The company has also developed a tissue extraction kit for extracting full-length proteins and short peptides from formalin-fixed paraffin-embedded (FFPE) tissue sections.